In Science this week: DNA Fountain for storing data in DNA, and more.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
Through the acquisition, Miroculus will be able to automate and simplify the detection of miRNAs from blood using Kapplex's digital microfluidic technology.
The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company plans to establish a clinical laboratory to offer its Gensignia miRNA Signature Classifier for Lung Cancer Test, as well as other tests in the future.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.
A team of researchers from the National Institutes of Health has identified three circulating microRNAs that were differentially expressed in the serum of older versus younger individuals in a small sequencing study.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.